Benzinga, founded in 2010 by Jason Raznick and headquartered in Detroit, Michigan, is a dynamic financial media and technology company dedicated to empowering individual investors with timely, actionable insights. Initially launched from Raznick’s basement with a modest $10,000 investment, the company has grown into a trusted resource, attracting approximately 25 million monthly readers through its innovative blend of real-time financial news, market analysis, and trading tools.
The U.S.'s longest-running government shutdown shows no sign of ending soon, with Rep. Tim Burchett (R-Tenn.) predicting it will stretch beyond Thanksgiving.
Nvidia CEO Jensen Huang praised TSMC for supporting surging Blackwell AI chip production amid tightening supply and new Trump administration restrictions on overseas sales.
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."
Defense Secretary Pete Hegseth is pushing contractors to speed up weapons production and pledged U.S. support to allies while overhauling Pentagon procurement.
The Supreme Court temporarily froze a lower court ruling that had compelled the Trump administration to immediately provide full federal food benefits to roughly 42 million Americans.
First Trust Advisors debuts its 300th ETF, giving investors exposure to companies powering the clean energy and tech revolution through essential metals.
Elon Musk's 2025 pay package was approved. Will the new compensation plan have the same impact as the 2018 plan for the Tesla CEO that helped boost the stock.
Lucid Group shares continued their slide Friday afternoon, following the company's third-quarter 2025 results released Wednesday, which missed analyst expectations.
Tech and AI-linked stocks suffered their worst week since April, with Palantir, Nvidia, and AMD plunging as investors took profits and bubble fears resurfaced.
Shares of Clearmind Medicine Inc. (NASDAQ: CMND) are falling Friday after the clinical-stage biotech company shared a key update about its stock listing.
